Serving hundreds of leading biopharmaceutical companies globally:

Generated: November 16, 2018

DrugPatentWatch Database Preview

Fresenius Medcl Company Profile

« Back to Dashboard

What is the competitive landscape for FRESENIUS MEDCL, and when can generic versions of FRESENIUS MEDCL drugs launch?

FRESENIUS MEDCL has nine approved drugs.

There are five US patents protecting FRESENIUS MEDCL drugs.

Summary for Fresenius Medcl

US Patents:	5
Tradenames:	22
Ingredients:	5
NDAs:	9

Drugs and US Patents for Fresenius Medcl

+ Get email alerts for changes to this table

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Medcl	DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER	calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate	SOLUTION;INTRAPERITONEAL	018883-002	Nov 30, 1984	AT	RX	No	No		➤ Sign Up				➤ Sign Up
Fresenius Medcl	DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER	calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate	SOLUTION;INTRAPERITONEAL	018379-002	Approved Prior to Jan 1, 1982		DISCN	No	No		➤ Sign Up				➤ Sign Up
Fresenius Medcl	DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER	calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate	SOLUTION;INTRAPERITONEAL	018379-006	Jul 7, 1982		DISCN	No	No		➤ Sign Up				➤ Sign Up
Fresenius Medcl	DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER	calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate	SOLUTION;INTRAPERITONEAL	018379-001	Approved Prior to Jan 1, 1982		DISCN	No	No		➤ Sign Up				➤ Sign Up
Fresenius Medcl	PHOSLO GELCAPS	calcium acetate	CAPSULE;ORAL	021160-003	Apr 2, 2001	AB	RX	Yes	Yes	6,576,665	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Expired US Patents for Fresenius Medcl

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Fresenius Medcl	PHOSLO	calcium acetate	CAPSULE;ORAL	021160-001	Apr 2, 2001	4,870,105	➤ Sign Up
Fresenius Medcl	PHOSLO GELCAPS	calcium acetate	CAPSULE;ORAL	021160-003	Apr 2, 2001	4,870,105	➤ Sign Up
Fresenius Medcl	PHOSLO	calcium acetate	CAPSULE;ORAL	021160-002	Apr 2, 2001	4,870,105	➤ Sign Up
Fresenius Medcl	PHOSLO	calcium acetate	TABLET;ORAL	019976-001	Dec 10, 1990	4,870,105	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Paragraph IV (Patent) Challenges for FRESENIUS MEDCL drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Oral Solution	667 mg/5 mL	➤ Subscribe	2013-12-05
➤ Subscribe	Capsules	EQ 169 mg calcium	➤ Subscribe	2005-05-31

International Patents for Fresenius Medcl Drugs

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
China	101522021	➤ Sign Up
Mexico	2009000722	➤ Sign Up
Hong Kong	1129814	➤ Sign Up
World Intellectual Property Organization (WIPO)	2008011126	➤ Sign Up
South Korea	101553719	➤ Sign Up
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for Fresenius Medcl Drugs

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2014000088	Germany	➤ Sign Up	PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT ATORVASTATIN ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE ATORVASTATIN ALS ATORVASTATINCALCIUMTRIHYDRAT; NAT. REGISTRATION NO/DATE: 90223.00.00 20141113; FIRST REGISTRATION: FRANKREICH CIS: 6 928 917 6 20140912
C/GB07/011	United Kingdom	➤ Sign Up	PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
C0018	France	➤ Sign Up	PRODUCT NAME: SACUBITRIL/VALSARTAN,SOUS FORME DE COMPLEXE SODIQUE SACUBITRIL VALSARTAN,C'EST-A-DIRE DE (3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL) PROPIONATE-(S)-3'-METHYL-2'-(PENTANOY(2''-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE)DE TRISODIUM HEMIPENTAHYDRATE; REGISTRATION NO/DATE: EU/1/15/1058 20151123
C0108	Belgium	➤ Sign Up	PRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522
00125	Netherlands	➤ Sign Up	PRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust

Farmers Insurance

Johnson and Johnson

Cerilliant

Boehringer Ingelheim

Argus Health

Accenture

Medtronic

Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.